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Abstract: Nanocarriers have been increasingly proposed for lung drug delivery applications. The 12 
strategy of combining the intrinsic and more general advantages of the nanostructures with 13 
specificities that improve the therapeutic outcomes of particular clinical situations is frequent. These 14 
include surface engineering of the carriers, by means of alteration of the materials structure (i.e. 15 
chemical modifications), the addition of specific ligands so that predefined targets are reached, or 16 
even the tuning of the carrier properties to respond to specific stimuli. The devised strategies are 17 
mainly directed to three distinct areas of lung drug delivery, encompassing the delivery of proteins 18 
and protein-based materials, either for local or systemic application, the delivery of antibiotics and 19 
the delivery of anticancer drugs, the latter two comprising local delivery approaches. This review 20 
addresses the applications of nanocarriers aimed at lung drug delivery of active biological and 21 
pharmaceutical ingredients, focusing with particular interest nanocarriers that exhibit 22 
multifunctional properties. A final section addresses the expectations regarding the future use of 23 
nanocarriers in the area. 24 
Keywords: Antibiotics, cancer, drug delivery, lung delivery, nanocarriers, nanopharmaceuticals, 25 
proteins.  26 
 27 
1. Introduction  28 
The appearance of new therapies and alternative strategies for the delivery of drug molecules 29 
has been changing the paradigm of therapeutic approaches [1-3]. Indeed, therapeutic solutions have 30 
been implemented around one of two possible objectives: one is the development of better and more 31 
effective therapies, usually involving new drugs; the other relies on exploring different ways to 32 
deliver molecules, potentiating their action and, in many cases, simultaneously, eliminating adverse 33 
effects or, at least, decreasing their impact. The latter approach has been often used for drug 34 
repurposing, finding new applications for de‑risked compounds, with potentially lower overall 35 
development costs and shorter development timelines. The literature displays some recent and 36 
valuable reviews on the topic of drug repurposing [4,5]. The adverse effects derived from 37 
pharmaceuticals have always caused concern, as some can be devastating, leading to therapeutic non-38 
compliance. Thus, exploring delivery strategies is as important as the discovery of new molecules 39 
and targets, providing the molecules with specific orientation towards their targets, avoiding major 40 
biological stresses and, overall, improving the therapeutic quality [6]. Actually, in many cases, the 41 
two referred approaches are addressed at a time. 42 
Considering that, in most cases, the delivery of unformulated drug molecules is not successful, 43 
formulation plays a role of utmost importance in therapy. Conventional drug delivery systems 44 
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encompass numerous restrictions, which include limited targeting, low therapeutic index, poor 45 
aqueous solubility, and the potentiation of drug resistance [7]. The design and production of systems 46 
in which drug molecules are included in a carrier, being either embedded in the matrix or adsorbed 47 
to the surface, is frequently the next step towards a more effective therapy. The reasons justifying the 48 
need for drug formulation are in the annals of pharmaceutical technology, going from a simple 49 
protection of drugs to the more complex targeting of cells or tissues. In between, the need to achieve 50 
control over drug release has also been a hallmark of drug delivery research. A useful historical 51 
perpective on the generations of controlled drug delivery systems is available in [8]. In fact, in an era 52 
where drug molecules are expected to answer to increasingly complex environments, their 53 
formulation takes on a role never seen. That role assumed, a great variety of advanced drug delivery 54 
systems has been reported through the years, with important variations on their properties, including 55 
size and composition. Size is one of the most relevant features in the field. In this context, both micro- 56 
and nanocarriers have been reported to be viable approaches, the final selection being objectively 57 
dependent on the specific application that is envisaged. The potential of micron-sized carriers has 58 
been highlighted for different applications [9-13], but lies out of the scope of this review. As for the 59 
nanoscaled carriers, in drug delivery these fall into the designation of nanopharmaceuticals, defined 60 
by Rivera Gil et al as “pharmaceuticals where the nanomaterial plays the pivotal therapeutic role or 61 
adds additional functionality to the previous compound” [14]. The International Organization for 62 
Standardization defines nanoparticles as those having at least one dimension less than 100 nm [15]. 63 
In turn, the American Food and Drug Administration (FDA) indicates that products involve 64 
nanotechnology, and should therefore be evaluated as such, when they are “engineered to exhibit 65 
properties or phenomena attributable to dimensions up to 1000 nm” [16]. This broader definition is 66 
the most typically seen in academic research in drug delivery and will be adopted in this review. 67 
Therefore, all submicron systems will be considered nanocarriers. 68 
As well indicated in the historical description of [8], after an initial period back in the 1980s and 69 
1990s, where many micron-sized formulations became popular and reached the market, 70 
nanotechnology has been leading the interest of drug delivery scientists since the turn of the new 71 
century. In fact, the first mention to a system capable of encapsulating a molecule and providing its 72 
transport through a membrane dates back to 1965, under the name of liposome [17], which is, indeed, 73 
a nanosystem. From that point on, many other nanoformulations were described and explored, some 74 
of them consisting in particulate-based systems, with significant structural differences comparing 75 
with the vesicle-based systems comprised by liposomes. Particulate carriers at the nanoscale include 76 
polymeric nanoparticles [18], solid lipid nanoparticles [19,20], nanostructured lipid carriers [21,22] 77 
and magnetic and silica nanoparticles [23,24]. Probably, issues like increased stability [6], the closer 78 
interaction with cell structures [25], the propensity to provide increased drug absorption [26] and the 79 
great ability for surface functionalisation [27] have driven the higher popularity of these materials. 80 
Regrettably, the clinical translation of nanoparticulate-based systems is very limited so far and only 81 
one formulation is available in the market: Abraxane®, marketed since 2005 [28]. This comprises 82 
albumin-conjugated paclitaxel, being used in metastatic breast cancer and non-small-cell lung cancer 83 
[29]. In this manner, despite the extensive research on particulate-based nanopharmaceuticals, their 84 
market absence is notorious, mainly due to tightened regulations. Even so, there are many 85 
nanoformulations currently undergoing clinical trials focusing varied routes of administration, and 86 
it is expected that some of them make their way into the market in some years [30].  87 
From the referred formulations undergoing a translational process and to the knowledge of the 88 
authors of this review, none is directed to lung drug delivery. Nevertheless, this is a delivery route 89 
that has been gaining popularity in recent years, essentially owing to its non-invasiveness and the 90 
increased demonstration of its potential, not only for local therapies, but also to provide systemic 91 
action. Actually, according to the World Health Organization (WHO), chronic obstructive pulmonary 92 
disease (COPD), lower respiratory infections and lung cancer are, respectively, the third, fourth and 93 
sixth causes of death worldwide [31], which illustrates the existing therapeutic limitations. In 94 
addition, numerous other respiratory disorders are characterised by an urgent and unmet therapeutic 95 
need. The myriad of routes of administration poses the question of which one is the most adequate 96 
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to deliver a drug intended to treat a specific disease. In parallel, the search for routes of administration 97 
other than the oral has been increasing for some years. The lung is now being taken into high 98 
consideration for this purpose, as clearly demonstrated in Figure 1, where the number of publications 99 
per year that specifically refer to “lung drug delivery”, as retrieved from ISI Web of Science, can be 100 
observed. It has been considered a viable alternative in the delivery of drugs and the popularity of 101 
this delivery route is reflected in the growing number of publications, especially from 2014 onwards, 102 
indicating a clear interest from the scientific community.  103 
 104 
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 108 
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 111 
 112 
 113 
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 118 
Figure 1 – Number of scientific publications under the topics of “lung drug delivery” (blue) and “lung 119 
drug delivery and nano” (orange) on ISI Web of Science, as function of the publication year (last 120 
updated in January 2020). 121 
The established popularity of the lung route relies on several advantages and specific features. 122 
Apart from the already mentioned ability to provide either local or systemic effect, characteristics 123 
such as high vascularisation and extensive area available for absorption are highly appealing for 124 
systemic delivery, while the low metabolic activity compared with the oral route serves both 125 
modalities [32]. Furthermore, the possibility to use lower doses and the low incidence of systemic 126 
side effects are relevant pros for local delivery [33]. A very useful and up-to-date review on the 127 
challenges and opportunities of lung delivery can be found in [33]. Despite the mentioned 128 
advantages, some limitations are also to be referred, which mainly include the mucociliary clearance 129 
as the main mechanism of defence, the patient variability on pathophysiological aspects of the organ 130 
and the need to endow the drugs with suitable aerodynamic properties to reach a specific area of the 131 
lung [34]. Regarding the latter aspect, the aerodynamic diameter of the drugs or carriers to be 132 
delivered through inhalation assumes a crucial role. The aerodynamic diameter is the diameter of a 133 
spherical particle with density of 1 g/cm3 and the same settling velocity as the particle of interest. In 134 
this context, it is reported that the smaller airways can be reached by particles with aerodynamic 135 
diameter lower than 5 μm, while those with less than 2 μm may arrive to the respiratory zone, which 136 
includes the alveoli [32].  137 
Drugs have been administered by inhalation for millennia, but inhaled therapeutics have been 138 
used predominantly to manage common pulmonary diseases like asthma and COPD. In these areas, 139 
inhalable drugs have been dominating the market. Systemic formulations, in turn, have been facing 140 
many limitations, with significant technical hurdles requiring being addressed before success is 141 
achieved. Nevertheless, it has become consensual that, given the offered advantages, the posed 142 
challenges are worth addressing. The possiblities have long been debated, especially considering the 143 
emergence of biological drugs that are degraded in the gastrointestinal tract and, so, rely uniquely 144 
on injection to find efficacy. The scientific community has, thus, been recognising the potential of the 145 
lung to be used as a systemic pathway, and many of the papers contributing to Figure 1 deal with 146 
systemic lung delivery, although so far this interest is not mirrored by the market. In fact, inhalable 147 
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insulin is one of the exceptions to mention, appearing first as Exubera®, from Pfizer (2006), but being 148 
discontinued one year after approval [35,36], the company justifying the withdrawal with ‘comercial 149 
reasons’. Another product of inhalable insulin became available in 2014, as Afrezza®, from Mannkind 150 
Corporation, and incorporates the Technosphere® technology [36,37]. These inhalable insulin 151 
products are not based on nanotechnologies, but the scientific community has been recognising the 152 
potential of nanocarriers in lung delivery and nanoformulations have been increasingly proposed, as 153 
can be also observed in Figure 1. An integrated analysis of this figure shows that publications 154 
involving nanosystems usually comprise more than half of the total number of publications on the 155 
topic of lung delivery, which demonstrates well their popularity. In fact, the superiority of 156 
nanosystems has been demonstrated in certain applications of the respiratory field, as will be 157 
described in the following sections of the review. The nanocarriers permit drug protection, provide 158 
a greater ability to interact with the tissues and cells, owing to the high surface area, often allowing 159 
specific targeting and/or controlled drug release [38]. However, the proposal of nanocarriers must 160 
not be blind and it is important to note that some applications may take greater benefit from the use 161 
of microcarriers, for example if the therapeutic target is phagocytic cells such as macrophages. 162 
Moreover, despite the large amount of works describing nanocarriers for lung delivery applications, 163 
it is worth saying that a closer reading of the searched documents reveals that many of the works 164 
propose the nanocarriers as having potential from a conceptual point of view, but a much smaller 165 
amount approaches the practical concept of preparing the carriers for inhalation, endowing them 166 
with the required properties, namely aerodynamic, for the purpose. 167 
While initial approaches on the development of drug nanocarriers essentially addressed issues 168 
of drug stability and control over the release, these were rapidly replaced or completed with 169 
advanced techniques of particle engineering. Thus, the proposal of more complex carriers naturally 170 
came along, with particle engineering techniques endowing the nanocarriers with specific properties 171 
well beyond their role of carrying a drug or molecule of interest. Such carriers were named as 172 
multifunctional and their applications have been explored in all areas of delivery. The 173 
multifunctional nanocarrier can be one composed of a material that provides, itself, a specific 174 
function, or one that was modified to exhibit a determined feature. Lung delivery can strongly benefit 175 
from the features of these carriers. In fact, while most asthma and COPD drugs are delivered to the 176 
lung with relatively low efficiency and still ensure therapeutic efficacy, drugs aimed at a systemic 177 
action or used to treat orphan diseases or cancer, require optimisation of delivery efficiency. This will 178 
render the treatment cost-effective, while potentiating clinical effectiveness and minimising side 179 
effects.  180 
Considering the interest of nanocarriers within the context of lung drug delivery, this review 181 
will focus on their applications, placing particular emphasis on the functionality that is provided by 182 
the proper carriers. For the effects of the review, only works addressing directly the issue of 183 
pulmonary administration of the carriers, either by adequate in vitro testing or by suitable in vivo 184 
delivery, will be considered, thus going beyond the theoretical concept of suitability for lung delivery 185 
purposes. The specific features of the carriers will be referred and the achieved outcomes described. 186 
The envisaged applications of the nanocarriers in lung delivery are diverse, but particularly address 187 
the delivery of proteins or protein-based materials, either for local or systemic effect [39,40], cancer 188 
treatment [41,42] and local delivery of antibiotics [43,44]. Therefore, the review will specifically focus 189 
on these topics. As an introductory element to the following sections, Table 1 depicts the major 190 
respiratory diseases, along with their main limitations and the potential improvements imparted by 191 
pulmonary delivered therapy. 192 
 193 
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Table 1 – General overview of the major respiratory diseases, along with their main limitations and improvements imparted by pulmonary delivery of the 194 
drugs. Indication of the application, in each disease, of the drug classes addressed in the review.  195 
 196 
CFTR: Cystic fibrosis transmembrane conductance regulator; COPD: chronic obstructive pulmonary disease 197 
n.a.: not applicable; *conventional therapy already administered via inhalation 198 
Respiratory 
disease 
Main limitations Improvements from lung delivery Proteins Antibiotics 
Anticancer 
drugs 
Asthma 
Low therapeutic efficacy of delivered drugs; 
inefficient control of the disease; airway 
inflammation 
n.a.*  x   
COPD 
Persistent inflammation; parenchymal lung 
tissue destruction; abnormalities of the small 
airways 
n.a.* x x  
Pneumonia 
Low amount of drug reaches infection site; 
antimicrobial resistance 
Higher drug accumulation in infection site; co-
localisation of drug and infectious agent 
x x  
Cystic fibrosis 
Thick viscous mucus; recurrent lung 
infections; progressive impairment of lung 
airways 
Mucus-penetrating carriers; increased lung 
drug retention; delivery of genetic material to 
restore CFTR function 
x x  
Tuberculosis 
Reduced amount of drug reaches infection 
site; antimicrobial resistance; long 
therapeutic regimen 
Co-localisation of drug and infectious agent; 
reduction of antibiotic resistance incidence; 
possibility of add-on therapy (along with oral); 
reduce treatment duration 
 x  
Lung cancer 
Non-specificity of drugs; difficulties to reach 
the affected tissues; severity of systemic 
adverse effects 
Vectorisation to cancer cells; reduction of 
systemic adverse effects 
  x 
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2. Lung drug delivery mediated by multifunctional nanocarriers 199 
Multifunctional nanocarriers can be produced from a wide range of materials. In parallel, it is 200 
also wide the number of molecules that can be associated to the carriers to provide specific effects 201 
and improve their perfomance, either being adsorbed or chemically-bound. This variety arises from 202 
the necessity to meet different challenges and address a vast number of diseases with intrinsic 203 
different characteristics.  204 
In the present section, the three main topics mentioned above will be approached. As a summary 205 
of the contents, Figure 2 provides a depiction of the type of carriers used in each topic, along with the 206 
materials selected for nanoparticle matrix and surface modification, when applicable, and also the 207 
associated molecules of interest. 208 
 209 
Figure 2 – General overview of the types of nanocarriers used in the delivery of proteins, 210 
antibiotics and anticancer drugs, along with the materials applied in the carrier matrix (inside the 211 
circle), the ligands used for surface functionalisation and the associated molecules of interest (the 212 
cargo). The circle indicates the carrier. BSA: bovine serum albumin, EpCAM: epithelial cell adhesion 213 
molecule, HSA: human serum albumin, IgG: immunoglobulin G, NP: nanoparticles, PEG: 214 
polyethylene glycol, PEI: polyamidoamine, PGA-co-PDL: poly(glycerol adipate-co-ω-215 
pentadecalactone), PLA: polylactic acid, PLGA: polylactic-co-glycolic acid, RGD: tripeptide Arg-Gly-216 
Asp, siRNA: small interfering RNA, SLN: solid lipid nanoparticles, SPIO: superparamagnetic iron 217 
oxide, TRAIL: tumor necrosis factor-related apoptosis-inducing ligand, #copolymer based on 218 
methoxy poly(ethylene glycol)-poly(ethylenimine)-poly(L-glutamate), *lipids: glyceryl 219 
monostearate, cholesterol. 220 
2.1. Delivery of proteins and protein-based materials 221 
The marked biotechnological advances observed in recent decades resulted in the appearance 222 
of many protein-based drugs. Fundamentally, the oral delivery of these molecules is prevented by 223 
the degrading effect of abundant protease content and the possibilities of delivery are essentially 224 
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reduced to injection-based strategies. However, this approach is more expensive and not appreciated 225 
by the patients, mainly due to the discomfort associated with the administration, but also because of 226 
some issues related with aesthetics, including bruising and skin marks that may compromise 227 
therapeutic compliance [45]. The pulmonary route thus appears as a sound alternative when a 228 
systemic effect is desired, but protein-based drugs also find applications in the treatment of local lung 229 
diseases. In fact, the first inhaled protein reaching the market was recombinant human DNase 230 
(rhDNase), indicated in the treatment of cystic fibrosis and available since the late 90s. Inhalable 231 
insulin appeared approximately 10 years after and lessons learnt from its development resulted in 232 
the current availability of many elegant inhalation devices and formulations. So far, no other inhaled 233 
biological drug aimed at systemic delivery reached the market, despite those being the drugs 234 
focusing most of the attention within the context of systemic delivery mediated by inhalation. None 235 
of the referred marketed formulations encompasses the use of nanocarriers. Actually, members of 236 
our group participated in the first work proposing the inhalation of insulin encapsulated in polymeric 237 
nanoparticles, dated back to 2005 [39,46,47]. At that time, chitosan was proposed as matrix material, 238 
resulting in non-toxic nanoparticles and endowing the system with mucoadhesivity [48]. In order to 239 
provide the nanoparticles with suitable aerodynamic properties to reach the alveolar zone, a nano-240 
in-micro system was developed, using spray-drying to microencapsulate the nanoparticles in 241 
mannitol microspheres. These, expectedly released the nanoparticles after dissolving in the lung 242 
lining fuid, providing the release of the protein that could, thus, be absorbed systemically [39]. An in 243 
vivo study in rats evidenced that microencapsulated insulin-loaded chitosan nanoparticles 244 
administered intratracheally (IT, 16.7 IU/kg) induced a more pronounced and prolonged 245 
hypoglycemic effect compared with insulin solution, as observed in Figure 3 [47], thus demonstrating 246 
the contribute of the carrier itself to the observed therapeutic effect. A similar approach was later on 247 
proposed by other authors, using poly-L-lysine to modify the surface of self-assembled pure insulin 248 
nanoaggregates, benefiting from the adhesive properties of poly-L-lysine. After IT administration to 249 
diabetic rats, the modified nanostructures (5 IU/kg) induced hypoglycemic effect as stronger as 250 
subcutaneous delivery (1 IU/kg), but increasing the drug half-life from 1.28 h to 2.75 h. Although not 251 
statistically significant, the hypoglycemic effect obtained from nanoparticles was also more 252 
prolonged, achieving 23.4% relative bioavailability [49].  253 
 254 
 255 
 256 
 257 
 258 
 259 
 260 
 261 
 262 
 263 
 264 
 265 
 266 
 267 
Figure 3 – Hypoglycemic profiles following intratracheal administration to rats of 268 
microencapsulated insulin-loaded chitosan nanoparticles (INS-loaded CS NPs) prepared using 269 
chitosans of different MW (CS 113 and CS 213), and control formulations (mean ± SD, n ≥ 3): (♦) 270 
Microencapsulated INS-loaded CS NPs — CS 113; (■) Microencapsulated INS-loaded CS NPs — CS 271 
213; (○) Microencapsulated blank (without insulin) CS NPs — CS 113; (□) Mannitol microspheres 272 
containing INS; (∆) Suspension of INS-loaded CS NPs — CS 113; (●) INS solution in PBS pH 7.4; 273 
*Statistically significant differences from microencapsulated blank CS NPs (p < 0.05); #Statistically 274 
significant differences from INS solution (p < 0.05). Reprinted with permission from [47]. 275 
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Solid lipid nanoparticles (SLN) were also proposed for this end and were reported to provide 276 
homogeneous distribution through the lung upon delivery to diabetic rats by nebulisation, showing 277 
relative bioavailability of insulin of 22.3% comparing with subcutaneous injection [50]. An approach 278 
similar to that referred above of chitosan nanoparticles microencapsulated in mannitol microparticles 279 
was later reported for the systemic delivery of calcitonin. The inhalable carriers had mass median 280 
aerodynamic diameter (MMAD) of 2.7 μm and fine particle fraction (FPF) of 64%, the latter 281 
representing the fraction of particles with aerodynamic diameter lower than 5 μm [51]. After IT 282 
administration, around 85% relative bioavailability was determined, comparing with subcutaneous 283 
delivery. The bioavailability was also superior to that obtained after inhalation of native calcitonin 284 
[52]. Another approach in the same line, proposed the delivery of IgG mediated by poly(lactic-co-285 
glycolide) acid (PLGA)-based nanoparticles produced by double emulsification and subsequently 286 
spray-dried to acquire suitable aerodynamic properties. Leucine was further included to improve 287 
aerosolisation. MMAD around 4 μm and FPF of approximately 50% indicated suitability to reach the 288 
deep lung, while a prolonged release up to 35 days was observed in PBS pH 7.4, enabling applications 289 
where prolonged release is envisaged [53]. 290 
More than simply avoiding injections, the driving force fostering investment on systemic drug 291 
delivery through the lung relies on the improvement of pharmacokinetics, which could be an 292 
advantage for drugs currently delivered through the oral, buccal or transdermal routes. The studies 293 
reported above reinforce the potential of the lung to provide an access to the systemic compartment, 294 
but above all, they show that the nanocarriers can play a role in improving the therapeutic 295 
performance. Nevertheless, one of the limitations that is relatively tranversal to works on lung 296 
delivery is the fact that, in most cases, the in vivo testing of inhalable formulations is performed by IT 297 
administration, which does not mimic the reality when human delivery is concerned. This aspect still 298 
requires some advancement in order to better predict in vivo outcomes. 299 
The delivery of drugs that are specifically directed to the lung, is the other side of the picture of 300 
lung delivery. Local treatment of lung diseases usually aims at low systemic bioavailability in order 301 
to avoid the risk of unwanted side effects in other organs due to rapid drug translocation via the air-302 
blood barrier. Some respiratory pathologies are ineffectively treated with existing small molecule-303 
based therapies. RNAi effectors, such as small interfering RNA (siRNA), have shown to enable the 304 
post-transcriptional silencing of key molecular disease factors that cannot be readily targeted with 305 
conventional small molecule drugs [54]. Therefore, some therapeutic alternatives are currently being 306 
proposed in this context. The type of cell that is targeted in this approach is variable and depends on 307 
the specific airway disease. Epithelial cells are key players in cystic fibrosis, for instance, while 308 
dendritic cells, macrophages and T lymphocytes are the targets in inflammatory diseases like asthma 309 
or COPD [54]. The local therapeutic response to siRNA can be markedly enhanced through the use 310 
of nanoparticles, essentially due to the possibility to provide specific cell targeting. The period of time 311 
that siRNA is retained in the lung plays an important role on the success of the approaches. This 312 
period is affected by rapid elimination due to mucociliary clearance, translocation to systemic 313 
circulation and secondary organs, and phagocytosis by alveolar macrophages. The complexation of 314 
siRNA with polyethylenimine (PEI), forming polyplexes, was demonstrated to reduce the 315 
translocation and extend siRNA retention time in lung, while preventing substantial phagocytosis by 316 
macrophages and avoiding extensive mucociliary clearance [55]. Additionally, it has been shown in 317 
several occasions [56,57] that the contact of nanoparticles with the surfactant present in the alveolar 318 
zone leads to the coating of nanocarriers by a biomolecular corona, composed of lipids and proteins. 319 
This corona affects nanoparticle hydrophobicity and possibly enhances biorecognition, with 320 
consequences on the subsequent interactions with cells and other biological entities. Most works 321 
report a negative impact of this process on the therapeutic outcomes. Interestingly, with regards to 322 
the delivery of siRNA, recent works have suggested that modifying the surface of siRNA-loaded 323 
nanoparticles with lung surfactant (by a simple incubation) provides improved siRNA transfer 324 
activity due to facilitated cellular uptake [54]. Improved transfection efficiency of pDNA was also 325 
reported previously in presence of lung surfactant [58]. siRNA-dendrimer (polyamidoamine, 326 
generation 4) complexes of ~100-130 nm were microencapsulated in trehalose-inulin microparticles, 327 
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which displayed aerodynamic diameters of 4.5 – 5.5 μm, adequate to reach the deep lung. These 328 
microparticles dissolved in aqueous medium, releasing the nanocomplexes, which showed enhanced 329 
cellular uptake and transfection in RAW264.7 macrophages, comparing with native siRNA [59]. 330 
Protein-based molecules are, in many cases, regarded as sensitive and their manipulation in delivery 331 
devices such as inhalers is often feared. A study demonstrated the stability of mRNA upon 332 
nebulisation, showing no effect of nebulisation on protein duration of action or the cytotoxicity of the 333 
formed PEI polyplexes [60]. 334 
Inhalable vaccines have also been the focus of several works and, although many pulmonary 335 
vaccines have been proposed, only few involve nanocarriers. An interesting approach was reported 336 
that uses a double emulsion formed by water/PLGA in organic/lactose-water, with IgG, the model 337 
antibody, dissolved in the inner aqueous phase. The emulsion was spray-dried, resulting in PLGA 338 
nanoparticles within lactose microparticles. Suitable properties for inhalation were observed, with  339 
60% FPF. Submicron-particles were released after contact with aqueous medium, and approximately 340 
70% IgG released after 6 days in pH 7.4 [53]. Another approach reported poly(glycerol adipate-co-ω-341 
pentadecalactone) (PGA-co-PDL) nanoparticles that were modified to express on their surface the 342 
pneumococcal surface protein A, which is an important antigen of S Pneumoniae (~20 mg antigen/mg 343 
of nanoparticles). Nanoparticles of approximately 150 nm were then microencapsulated in leucine 344 
microparticles to provide respirability. The latter registered MMAD of 1.7 μm and 74% FPF, which 345 
grants the ability to reach the broncho-alveolar zone, potentiating the uptake by dendritic cells, as 346 
demonstrated experimentally [61]. Silica nanoparticles were also reported for this end. Nanoparticles 347 
were associated with plant-derived H1N1 influenza hemagglutinin antigen (HAC1) and proposed as 348 
inhalable vaccine against influenza virus. A mucosal adjuvant (bis-(3’,5’)-cyclic dimeric guanosine 349 
monophos-phate (c-di-GMP)) was further tested. After IT vaccination of mice, the double-adjuvanted 350 
vaccine (nanoparticles plus mucosal adjuvant) were observed to induce high systemic antibody 351 
responses, comparable to the systemic vaccination control. Moreover, local IgG and IgA responses 352 
were observed in the bronchoalveolar lavage [62]. 353 
The described works clearly demonstrate that the lung provides a suitable route for the delivery 354 
of protein-based molecules, serving, in this context, the purpose of both systemic and local delivery. 355 
2.2. Delivery of antibiotics 356 
The delivery of antibiotics to the lung seems a very reasonable approach in the treatment of 357 
infections that are based in that organ. In fact, the most common routes of delivery of antibiotics are 358 
the oral and parenteral, even if the treatment of respiratory infections is intended. Addressing local 359 
lung infections requires reaching effective concentrations of drug in the organ, which implies the 360 
administration of significantly high doses and a general exposure of the organism to the drugs. The 361 
direct administration to the infection site would, thus, permit using lower doses and avoid or 362 
decrease systemic exposure, with the consequent reduction of systemic side-effects. Additionally, the 363 
more targeted delivery is a premise to decrease the incidence of antimicrobial resistance, an important 364 
current goal in antibiotic therapy [63,64]. Antibiotic resistance has been, for many years, one of the 365 
greatest public health problems. The increasing misuse of these molecules, ever since their discovery, 366 
has been making bacteria progressively resistant, by means of the development of specific cellular 367 
mechanisms. This has been continuously and consistently posing a renewed challenge to the 368 
treatment of infectious diseases [65].  369 
The market makes available some formulations of inhaled antibiotics, including tobramycin, 370 
colistin and aztreonan, which are mainly directed to the treatment of infections associatied with cystic 371 
fibrosis conditions [66]. Other applications have been reported occasionally, such as the use of 372 
aerosolised antibiotics in hospital-acquired pneumonia [67]. Research in the area has been increasing 373 
consistently and a recent review on inhalable antibiotic formulations is available in [66]. Along with 374 
the discovery of new antibiotics, the development of delivery systems to improve the therapeutic 375 
performance of the molecules has been object of scientific efforts and both approaches are, in fact, 376 
effective countermeasures against antibiotic resistance. The search for new drug molecules is known 377 
to be slower than the development of drug delivery systems that lead the antibiotics to the intended 378 
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site of action. Of the marketed formulations referred above, none is based on nanocarriers, but the 379 
literature provides many works reporting their use to improve the performance of lung delivered 380 
antibiotics, addressing, among others, the improvement of kinetic profiles and issues related with 381 
side effects. One of the most popular respiratory infections is tuberculosis, caused by Mycobacterium 382 
tuberculosis, which primarily accumulates and replicates inside alveolar macrophages located in the 383 
alveolar zone of the lung [68]. Despite the existence of effective therapy of tuberculosis for many 384 
decades, the fact is that it still remains a global epidemic, being a major healthcare problem, as 385 
portrayed by the last data published by WHO [69]. Not only the established therapy is prolonged 386 
and associated with severe side effects, which decreases therapeutic compliance, but also the issues 387 
of co-morbility with HIV and the existing bacterial resistance are relevant. A great number of works 388 
propose the use of nanocarriers for tuberculosis treatment, in many cases envisaging lung delivery 389 
applications. Very frequently, the developed carriers involve strategies of surface chemical 390 
functionalisation, namely mannosylation. The rationale behind this approach is based on the fact that 391 
bacterial hosts, the macrophages, have several surface receptors that are likely to be used as 392 
therapeutic targets [70,71]. The mannose receptor is one of the main, which may provide a favourable 393 
interaction with some units and chemical groups present on the carriers’ surface, including the 394 
mannose units, but also others like fucose and N-acetylglucosamine [72]. In principle, considering 395 
that the bacteria are hosted by the macrophages located in the alveoli, this is the zone to be reached 396 
in the design of any strategy aimed at treating tuberculosis by lung delivery.  397 
SLN have been proposed as carriers for this end. Rifabutin-loaded SLN prepared with glyceryl 398 
dibehenate (~100 nm) were further encapsulated in mannitol microparticles to acquire adequate 399 
aerodynamic properties to reach the alveolar zone (~44% of particles with less than 6.4 μm). An in 400 
vivo test in a murine model of infection (Mycobacterium tuberculosis strain H37Rv) demonstrated that 401 
the inhalation of the dry powder permitted effective delivery of the antibiotic to the lung, along with 402 
drug distribution to liver and spleen. Moreover, an enhancement of antibacterial activity was 403 
observed compared to nontreated animals [43]. Another formulation of SLN, this time composed of 404 
palmitic acid and cholesteryl myristate and loaded with rifampicin (~ 400 nm), was further freeze-405 
dried to obtain an inhalable powder. MMAD around 5 – 7 μm and FPF within 30% and 50% were 406 
determined. The SLN were mannosylated to improve their targeting ability, which was verified 407 
experimentally, with increased macrophage uptake (~80%) compared to non-functionalised SLN 408 
(~40%) [71,73]. Rifampicin was also the chosen antitubercular drug to encapsulate in polymer-409 
glycerosomes, which showed to be more stable than conventional liposomes [74]. These are 410 
phospholipid/glycerol vesicles combined with trimethyl chitosan or hyaluronic acid (80 – 110 nm). 411 
Upon nebulisation, MMAD of approximately 4 µm was obtained along with FPF up to 77%. In any 412 
case, the aerodynamic performance of the carriers was always better than that of the free drug and 413 
drug incorporation in the vesicles was found to increase its efficacy against Staphylococcus aureus. 414 
Following IT administration to rats, glycerosomes promoted the accumulation of rifampicin in the 415 
lung, with lower systemic distribution, and low accumulation in other organs. The formulation 416 
containing hyaluronic acid was found to perform more favourably [75]. Although it was not 417 
discussed, the use of hyaluronic acid might be beneficial due to a favourable interaction of its N-418 
acteylglucosamine units with CD44 [76,77] and mannose receptors [78]. Chitosan and chitosan-folate 419 
were further used to functionalise oleic acid-based nanoemulsions loaded with rifampicin, which 420 
were nebulised to render adequate respirability (MMAD of 3 – 4 μm and FPF of 62-73%). It was found 421 
that chitosan-folate provided increased cell internalisation, proposed to result from a favourable 422 
interaction with macrophages by both chitosan units and folate groups. Additionally, this 423 
formulation provided in vivo higher lung drug content and reduced plasma drug concentration [79]. 424 
Chitosan nanoparticles prepared by ionic gelation with tripolyphosphate were also proposed a 425 
couple of times as carriers in antitubercular drug delivery. A first work described the association of 426 
isoniazid and used spray-drying with lactose and leucine to reach an FPF of 45% [80]. More recently, 427 
similar nanoparticles associated bedaquiline (size varying within 70 and 700 nm depending on 428 
preparation conditions). A powder form of the nanoparticles was obtained by freeze-drying, 429 
registering 28% FPF and 3.38 μm MMAD, which was better than the conventional DPI formulation 430 
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used as control (15% FPF and MMAD of 4 μm). The study determined absence of toxicity of the 431 
nanoparticles in vivo in rats and further demonstrated higher drug concentration in lungs upon 432 
inhalation of the microencapsulated nanocarriers [81]. Frequently, the choice of chitosan as 433 
nanoparticle matrix material is not explicitly justified, leaving the readers with the sensation that the 434 
polymer is only used because of its high popularity, a natural consequence of its favourable 435 
properties regarding mucoadhesion and absence of toxicity. In this latter work, the authors justified 436 
the positive results with a possible favoured uptake of nanoparticles by alveolar macrophages 437 
mediated by an interaction of chitosan positive charges (from amino groups) with the negatively 438 
charged surface of macrophages. However, most of the works fail to point out that the strong affinity 439 
of macrophages by chitosan is possibly a result of the recognition of N-acetylglucosamine units of the 440 
polymer by macrophage surface receptors, as was proposed in a work from our group reporting 441 
chitosan microparticles as antitubercular drug carriers [78,82]. The use of chitosan as matrix material 442 
was also proposed in genipin-crosslinked carboxymetylchitosan nanoparticles loaded with isoniazid 443 
and rifampicin, which were freeze-dried to obtain a powder. After inhalation by rats, a greater 444 
accumulation of drugs was observed in the lung upon delivery of the carriers compared with the free 445 
drugs. Additionally, extended residence time of drugs in the lung was achieved and lower levels in 446 
other organs (liver, kidney) were registered [83].  447 
As a whole, several nanoparticle-based formulations are proposed in the frame of tuberculosis 448 
therapy, in most cases showing improved results attributed to specific functionalisation of their 449 
surface or benefits from their proper composition (e.g. chitosan). In order to provide adequate 450 
respirability, the nanocarries are either nebulised or transformed in inhalable powders using spray- 451 
or freeze-drying. In the works showing in vivo results, the delivery by inhalation tipically provided 452 
increased lung concentrations of the drug and lower systemic exposure. 453 
Other lung diseases work as a door for opportunistic infections, cystic fibrosis being a major 454 
example. This is a genetic disorder caused by mutations in the cystic fibrosis transmembrane 455 
conductance regulator (CFTR) gene. This gene is of the utmost importance, as it encodes a protein 456 
that forms an ion channel in epithelial cell membranes. The genetic disfunction may translate into 457 
different defects of the protein, in any case ending up in bronchial obstruction that occurs due to the 458 
secretion and accumulation of a thick and sticky mucus in the airways. The accumulation of mucus 459 
creates the adequate conditions for bacterial colonisation, which tipically involves Pseudomonas 460 
aeruginosa and Staphilococcus aureus [84-86]. This justifies that cystic fibrosis therapy requires regular 461 
administration of antibiotics, apart from bronchodilators and mucolytics.  462 
A solution of tobramycin for inhalation was the first approved aerosolised antibiotic to be used 463 
against P. aeruginosa and, recently, a dry powder form of tobramycin has become available. However, 464 
this drug shows poor mucus penetration, rapid clearance and suboptimal concentrations at the site 465 
of infection, which are frequently not enough to stop the complications derived from the bacterial 466 
infection [87]. The need for better therapies is one of the emmergent objectives in the field of cystic 467 
fibrosis. Nanotechnology can bring forth some solutions in this context. Mucus penetration is, indeed, 468 
a major issue. If it is possible to overcome this barrier, enabling a more effective delivery of drugs, 469 
infections can be eliminated with higher efficiency. In a very interesting work, Schneider et al. (2017) 470 
demonstrated that mucus penetrating nanoparticles (polystyrene nanoparticles coated with 471 
polyethylene glycol - PEG) of size up to 300 nm have higher retention in the lung and more uniform 472 
distribution compared with similar sized nanoparticles devoid of PEG and, thus, mucoadhesive [88]. 473 
Regretably, no biological assays were reported so far, either in vitro or in vivo. Colistin was 474 
encapsulated in PLGA nanoparticles which were further surface-modified with chitosan (270 nm) or 475 
polyvinyl alcool (PVA, 330 nm) and then spray-dried to reach adequate aerodynamic properties. 476 
MMAD less than < 5 μm was obtained when lactose was used as carrier, while the use of mannitol 477 
resulted in MMAD < 8 μm. In vitro assays revealed increased ability of chitosan-modified particles to 478 
penetrate artifical mucus and also suggested a role of the nanoparticles in potentiating the anti-479 
biofilm activity of colistin, possibly due to the ability of nanoparticles to penetrate the biofilm and to 480 
sustain drug release [89]. A previous work from the same group, where tobramycin was encapsulated 481 
in similar nanoparticles, demonstrated in vivo that PVA-modified nanoparticles reached the alveoli, 482 
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while particles modified with chitosan tend to appear in the upper airways, possibly as a consequence 483 
of their specific aerodynamic characteristics [90]. Ciprofloxacin was self-assembled with PEG-g-484 
phthaloyl chitosan nanoparticles (218 nm) and further microencapsulated by spray-drying in 485 
swellable alginate microparticles (volume mean diameter of 3.9 μm). Upon IT delivery to rats, the 486 
encapsulated molecule was found in higher concentration in lung tissue and lung lavage comparing 487 
with the administration of the control consisting of a physical mixture of lactose and micronised drug 488 
[91].  489 
Importantly, many bacteria regulate pathogenicity via a cell-to-cell communication system that 490 
is known as quorum sensing. This is dependent on cell density and involves the production of 491 
virulence factors to coordinate group behaviours [92]. Antibacterial strategies based on the inhibition 492 
of quorum sensing are currently growing and this represents, indeed, a novel form of therapy. A very 493 
interesting approach in the delivery of antibiotics for the treatment of Pseudomonas aeruginosa 494 
infection involved SLN (< 100 nm) loaded with a quorum sensing inhibitor. Nebulisation has resulted 495 
in MMAD of 2.2 μm and FPF around 85% was determined, enabling the deposition of a certain 496 
fraction in the bronchial region. The SLN demonstrated to penetrate into artifical sputum, but the 497 
most important finding was that the proper SLN have anti-virulent effect, acting in addition to the 498 
quorum sensing inhibitor to decrease the virulence factor pyocyanin [93].  499 
As can be verified, under the scope of antibiotic delivery, a great deal of attention is given to 500 
tuberculosis. Anyway, the number of works addressing antibiotic delivery mediated by nanocarriers 501 
that present a certain degree of multifunctionality while providing real demonstration of potential 502 
for lung delivery, represents only a fraction. Apart from tuberculosis, Pseudomonas aeruginosa and 503 
Staphilococcus aureus are the two main targets, being frequently associated with cystic fibrosis and 504 
pneumonia, although they can be also involved in hospital-acquired lung infections, for instance. It 505 
was demonstrated in the several works described that the nanocarriers can provide extra strength to 506 
antibiotic-mediated therapies. 507 
2.3. Applications in cancer therapy 508 
The WHO refers to lung cancer as one of the most lethal [94]. In 2018, 18.4% of cancer-related 509 
deaths were of lung cancer, and the number of new cases (11.8%) was one of the highest, on par with 510 
breast cancer [95]. WHO has a set of goals to fight cancer aggresively, and the development of new 511 
strategies in cancer treatment is a priority worldwide. Lung cancer can be categorised into non-small 512 
cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC is considered aggressive and 513 
comprises approximately 85% of all occurrences, in which various subtypes are included such as 514 
adenocarninoma and squamous cell lung cancer. SCLC is even more aggressive, comprising the 515 
remaining 15% of cases [96]. The high probability of metastasis derived from SCLC, and the 516 
frequently late diagnosis, contribute to the high mortatility [97,98]. At earlier stages, the treatment for 517 
both types of lung cancer is surgery, enabling the removal of the affected area. However, at later 518 
stages, chemotherapy and radiation are the valid options, often to reduce the tumor mass before any 519 
surgical procedure [97,99]. Regretably, these options have great impact on patient’s physiology, as 520 
both cancerous and healthy cells are attacked, resulting in symptoms that are difficult to manage. As 521 
a consequence, patient susceptibility to other diseases is increased.  522 
The scientific community has been working to develop more targeted therapies, which is 523 
facilitated by the increasing information on molecular pathways, specific receptors and cancer 524 
microenvironment, enabling different treatment approaches. Although the intravenous route is the 525 
most used to deliver anticancer drugs, inclusive in lung cancer, the use of the lung route is an 526 
alternative yet to be fully explored in lung cancer therapy. This approach would allow a more 527 
targeted delivery, reaching directly the affected area, possibly with higher effectiveness than that 528 
provided by systemic delivery. Importantly, the lung can be considered the main route for the 529 
delivery of anticancer drugs in cases of lung cancer, but can also be used as add-on therapy for the 530 
treatment of lung metastasis secondary to other cancers. Overall, it is considered that this approach 531 
would potentially enable the use of lower doses of anticancer drugs, with reduced systemic exposure 532 
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and consequent residual metabolisation of the molecules [100]. This strategy further helps on the 533 
reduction of adverse effects, contributing for the increased quality of life of the patients. 534 
The number of nanocarriers proposed for an application in lung cancer mediated by lung 535 
delivery is high. In most cases, a therapeutic effect is envisaged, but some of the works address 536 
diagnostic purposes. Although this is of great importance in cancer, especially at early stages of 537 
development, these strategies will not be detailed further, as they are out of the scope of the review. 538 
For further reading on this matter, Silva et al. (2019) and Mottaghitalab et al. (2019) comprise two 539 
comprehensive reviews on potential diagnostic stategies [101,102]. Therefore, only works on 540 
nanocarriers envisaging therapeutic approaches will be considered. 541 
The general observation of the literature indicates that, in most cases, the proposal of 542 
nanocarriers for an application in cancer therapy implies functionalisation, that is, carriers with some 543 
sort of surface modification that benefits their interaction with the tumour environment. One of the 544 
strategies often reported in this context relies on the use of a matrix that is added of molecules 545 
potentially recognised by cell receptors prevailing in cancer cells comparing with healthy cells. Such 546 
an approach was already discussed briefly in the previous section, referring to carriers endowed with 547 
cell targeting ability mediated by mannose moieties. In the context of lung cancer, lactoferrin-548 
chondroitin sulfate nanocomplexes (~190 nm) were reported to co-deliver doxorrubicin (Dox) and 549 
elagic acid. The latter was first converted into water soluble nanocrystals due to its hydrophobicity. 550 
The nanocomplexes were prepared by electrostatic interaction between lactoferrin and chondroitin 551 
sulfate and the two drugs incorporated during this process. Due to the overexpression of CD44 and 552 
lactoferrin receptors on the surface of lung cancer cells, these nanocomplexes were shown to have 553 
favoured cell recognition, mediated by chondroitin sulfate and lactoferrin content, respectively. The 554 
authors further hypothesised that clathrin-mediated endocytosis could have contributed favourably 555 
to the internalisation of nanocomplexes, as their size is within the range of the pore size of the clathrin 556 
receptor (up to 200 nm) [103]. Therefore, the functionality of these carriers is provided not only by 557 
their size but also by their composition, which ensures specific targeting ability. To provide adequate 558 
aerodynamics for lung delivery, the nanocomplexes were then microencapsulated into a mannitol 559 
matrix, reaching FPF close to 90% and MMAD of 2.56 um. After IT insufflation of the 560 
microencapsulated nanocomplexes in tumour-bearing mice, tumour growth biomarkers were 561 
quantified and revealed lower levels when the inhalable formulation was used, in comparison with 562 
the inhalation of free drugs or intravenous administration [42]. 563 
These cell recognition strategies were also addressed in works with gold nanoparticles. Such 564 
carriers have strong interest in cancer therapy, finding applications in photothermal therapy, 565 
radiotherapy and also as drug carriers. Their inhalation has been demonstrated to provide lung 566 
accumulation, which can be useful in lung cancer therapy [104]. A very recent review on the topic is 567 
available in [105]. Gold nanoparticles (2 nm) that were coated with functional derivatives of thiolated 568 
PEG have shown invisibility towards the immune system provided by PEG [106], but also enabled 569 
attaching other moieties to provide specific targeting. The surface of the nanocarriers was thus 570 
modified with the ligand RGD, a peptide with relatively high and specific affinity for integrins 571 
overexpressed in tumour neovasculature [107,108]. A mice model of single-nodule lung 572 
adenocarcinoma [109] was used to establish which route of administration, either inhalation or 573 
intravenous delivery, would be more effective on adenocarcinoma targeting using the nanocarriers. 574 
The biodistribution data demonstrated higher concentration of the carriers upon inhalation [110]. In 575 
another approach, gold nanoparticles were loaded with temozolomide (~40 nm), an alkylating agent 576 
already in use in other cancer types. The IT administration to healthy mice indicated the safety of 577 
gold nanoparticles upon quantification of lactate dehydrogenase and the tumour markers 578 
carcinoembryonic antigen and alpha-fetoprotein. The proper carriers were reported to induce 579 
oxidative damage and ability to inhibit cell proliferation and cell cycle in G1-phase, while the delivery 580 
of drug-loaded carriers to mice bearing lung cancer demonstrated a synergic effect between the 581 
carriers and the loaded drug [111]. 582 
The optimisation of the interaction of nanocarriers with cancer cells has also been reported using 583 
SLN. A complex nanodelivery system based on SLN was proposed, being composed of multi-584 
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compartmental lipid nanocomposites (190-225 nm). Berberin and rapamycin, with demonstrated 585 
synergic anticancer effect, were initially encapsulated in SLN. To optimise the rate of delivery of both 586 
drugs, multicompartment systems were developed. Berberin was incorporated as hydrophobic ion 587 
pair with sodium dodecyl sulfate in SLN’s core, sustaining its release, while rapamycin was pre-588 
formulated as phospholipid complex, thus helping to improve its solubility and relatively enhance 589 
its release. The tumour targeting ability was improved by layer-by-layer assembly of the cationic 590 
lactoferrin and the anionic hyaluronic acid, which target the CD44 and lactoferrin receptors 591 
overexpressed by lung cancer cells. Adequate aerodynamics were achieved after spray-drying with 592 
a mixture of mannitol/maltodextrin/leucine (MMAD of 3.3 μm, FPF of 56%). An assay in mice bearing 593 
lung tumour demonstrated that inhaled nanocomposites induced a decrease of lung weight 594 
comparing with the inhalation of free drugs, along with reduction of tumour size and levels of 595 
angiogenic markers [112]. Another work proposed the modification of SLN surface with a chitosan 596 
derivative that was previously added of folate moieties [113]. The authors hypothesised that both the 597 
chitosan derivative and the folate engraftments would increase the retention of the nanoparticles 598 
within the lungs, and activate the folate receptors, increasing the amount of drug delivered to cancer 599 
cells. The nanocarriers (~250 nm; +32 mV) provided slower release of paclitaxel after coating (58% in 600 
3 days) and demonstrated binding affinity to cell lines expressing the folate receptor. In in vivo assays, 601 
higher lung paclitaxel concentration was observed for the inhaled chitosan-coated SLN compared 602 
with the intravenous administration of the drug. Moreover, drug concentration was higher at 1 h and 603 
6 h post-administration for the coated formulation compared with inhaled and intravenous delivered 604 
paclitaxel. As a final remark for this study, the authors noticed that the SLN were distributed 605 
throughout the solid lung tumours, with low interaction with the vessels, which occurs with systemic 606 
delivery of anticancer agents. Paclitaxel was also loaded in PEG-polylactic acid (PLA) nanoparticles 607 
that were further conjugated with the epithelial cell adhesion molecule (EpCAM, CD326), also 608 
overexpressed in lung cancer. IT delivery of nanoparticles to c-Raf transgenic lung cancer mice 609 
permitted reducing drug toxicity, with animal surviving increasing from 20% to 70% [114]. Another 610 
approach proposed lipid polymeric nanoparticles (hydrophobic polymeric core, phospholipid layer 611 
and an outer layer of epidermal growth factor (EGF), PEG and distearoylphosphoethanolamine) 612 
targeting the EGF receptor (EGFR) [115], which is overexpressed in lung carcinoma [116,117]. 613 
Cisplatin and Dox were the associated drugs. The presence of EGF in the outer part of the 614 
nanoparticle promoted the interaction with EGFR, leading to the release of drugs at the cancer site. 615 
An in vivo assay revealed tumour inhibition ratio of ~75%. 616 
Chitosan-coated PLGA nanoplexes were proposed to carry an antisense oligonucleotide against 617 
the human telomerase RNA component, as telomerase activity is detected in most NSCLC. The 618 
potential of the oligonucleotide as a telomerase inhibitor has been described [118], although its poor 619 
cellular uptake hinders its use in cancer therapy. The nanoplexes (±160 nm) were delivered IT to 620 
healthy mice, using the model of the isolated perfused and ventilated lung, and provided increased 621 
uptake of the oligonucleotide by the epithelium than that observed for the free form of the 622 
oligonucleotide. Although no specific study was performed, the authors justified the results with the 623 
potential ability of nanoparticles to escape pulmonary clearance mechanisms [119]. 624 
A solution towards a resistant form of cancer was proposed as inhalable self-assembled 625 
nanoparticles comprised of human serum albumin (HSA), tumor necrosis factor (TNF)-related 626 
apoptosis-inducing ligand (TRAIL) and Dox [120]. The latter was conjugated to HSA and formed 627 
nanoparticles, which were then coated with TRAIL (342 nm). Initial tests in H226 cells, which are 628 
representative of NSCLC, have shown that the simultaneous presence of Dox and TRAIL enabled 629 
increased cytotoxic potential, as cell viability after 3 days of exposure decreased from approximately 630 
60% when only one of the molecules was present in HSA nanoparticles, to 20-30% after dual 631 
association. An in vivo assay was then performed in lung tumour-bearing mice, delivering the 632 
nanoparticles in the form of micron-sized liquid droplets. The tumours of mice treated with HSA 633 
nanoparticles combining TRAIL and Dox were much smaller and lighter than those of mice treated 634 
with the corresponding nanoparticles containing only one of the molecules, TRAIL or Dox. 635 
Haloperidol was also used as ligand to enhance targeting ability of albumin-based nanoparticles (218 636 
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nm). Nanoparticles were prepared by desolvation of bovine serum albumin, previously conjugated 637 
with haloperidol and loaded with Dox. Spray-drying with mannitol, trehalose and leucine resulted 638 
in nano-in-microparticles with aerodynamic diameter of 4.6 μm and FPF of 66% [121]. 639 
Some works further report therapeutic approaches that rely on the ability of the carrier matrix  640 
to respond to different stimuli [122,123]. Modification of temperature and pH are usual stimuli to be 641 
used [124], setting the basis for the elaboration of the so called smart polymers or systems. The rationale 642 
behind their use is that a certain stimulus (pH value or temperature that is reached), will trigger a 643 
phase transition in the carrier matrix, leading to the release of the drug in a predetermined site. In 644 
this context, a copolymer based on methoxy poly(ethylene glycol)-poly(ethylenimine)-poly(L-645 
glutamate) was produced and nanoparticles prepared (< 75 nm), using electrostatic interaction and 646 
chelate effect to encapsulate simultaneously Dox and cisplatin [125]. In vitro assays demonstrated 647 
increased release of Dox at acidic pH, showing the capacity to release the drug in a cancer setting. 648 
The pulmonary administration of the nanocarriers to mice with metastatic lung cancer was 649 
performed using a Microsprayer aeroliser, resulting in increased accumulation of carriers within the 650 
lungs, along with low concentration in other tissues, especially in the area surrounding tumour 651 
lesions. It was hypothesised that the smaller size of the carriers benefitted their penetration in the 652 
cancer mass, while an inneffective vessel arrangement prevented a systemic dissemination. The 653 
results also shown decreased tumour masses, suggesting increased efficacy of the nanoformulation.  654 
Dendrimers of poly(amidoamine) were also used in a similar pH stimulation strategy. Dox was 655 
conjugated with the polymer and the dendrimers were spray-dried with mannitol to endow suitable 656 
aerodynamic characteristics (FPF was 40-60%). Dendrimers readily released from microparticles in 657 
aqueous medium and drug release was only found to occur in response to intracellular pH drop [126]. 658 
In another work, similar dendrimers showed strong time-dependent toxicity in Calu-3 cells, a model 659 
of the respiratory epithelium, which was attributed to sustained drug release. It was also shown that 660 
the conjugation of PEG molecules to the dendrimer improved their permeation across the cell layer, 661 
in a concentration-dependent manner. In this case, the dendrimers were formulated in a pressurised 662 
metered dose inhaler, leading to aerosols with 82% FPF and MMAD of 1.3 μm [127]. Dendrimers of 663 
PEGylated polylysine, also conjugated with Dox, were IT administered to a syngenic rat model of 664 
lung metastised breast cancer. An administration twice a week led to over 95% reduction in lung 665 
tumour after two weeks, comparing with IV administration of Dox solution, which resulted in a 666 
reduction of 30%-50% [128].  667 
In some cases, a combination of the above-mentioned strategies is proposed, as happens in a 668 
work reporting a stimuli-responsive core-shell nanoparticle conjugated with folic acid. The rationale 669 
behind this formulation was to create a pH- and temperature-sensitive network, comprised by a 670 
copolymer of poly(N-isopropylacrylamide) and carboxymethylchitosan, which comprises the shell 671 
of the nanosystem. In turn, the core is comprised of PLGA and an image contrast agent 672 
(superparamagnetic iron oxide, SPIO). While PLGA allows the controlled release of the encapsulated 673 
molecules, gemcitabine in this case, SPIO serves the dual role of contrasting agent and inductor of 674 
temperature change by external application of an alterning magnetic field. SPIO-induced 675 
temperature alterations lead to conformational change of polymeric shell, allowing drug release. 676 
Additionally, the shell of the system is pH-sensitive, providing drug release at the acidic pH 677 
characteristic of cancer environment. Moreover, the delivery is even more targeted owing to the 678 
surface conjugation with folic acid, benefitting from the overexpression of the folate receptor in 679 
cancer cells [129]. The nanocarriers (~289 nm, -36 mV) evidenced increased cell uptake in the presence 680 
of a magnet, as a consequence of the presence of SPIO in the formulation. In vivo assays in lung 681 
tumour-bearing mice show decreased tumour volume comparing with the controls. Pulmonary 682 
retention of nanoparticles was confirmed by magnetic ressonance imaging (MRI) and, when coupled 683 
with radiotherapy, a synergic effect takes place to slow tumour growth.  684 
Finally, magnetic nanoparticles have also been proposed several times within the scope of lung 685 
cancer. Many reports explore an application in lung cancer diagnosis, using Fe3O4 paramagnetic cores 686 
[130] or gadolinium-based particles [131,132], in the latter further enabling a radiosensitising effect. 687 
Nevertheless, therapeutic actions are also proposed. Iron oxide nanoparticles (Fe3O4; 56 nm, -49 mV) 688 
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were spray-dried with lactose and doxorubicin, reaching an MMAD of 3.27 μm. An in vitro study 689 
demonstrated that, comparing with a liquid suspension, the microencapsulated nanoparticles 690 
provided more than twice deposition and retention of particles in regions under the influence of a 691 
strong magnetic gradient [133]. 692 
 693 
As a whole, several different strategies are described that end up with positive results in lung 694 
cancer treatment. Nevertheless, cancer research still has much ground to cover and the associated 695 
therapeutics are growing at the rate of decipheration of new receptors and new molecular cascades. 696 
Nanotechnology is progressing along these discoveries, to provide improved strategies of cancer 697 
treatment. Those described above are dominated by the optimisation of the carriers surface, either by 698 
engineering with specific ligands, by carefully selecting the matrix components or by combining all 699 
the effects, in order to provide more targeted delivery of the drugs and an intimate contact with 700 
cancer cells, which will thus result in improved therapeutics.  701 
 702 
3. Expectations for the future 703 
Pharmaceutical technology has been playing a vital role on medicine, as it allows exploring 704 
different materials and their combinations to prepare drug carriers and to further endow these with 705 
better properties that enable reaching the desired target sites, ending up with therapeutic success. 706 
Many questions arise around the topic of nanocarrier-based lung drug delivery. Scientists have been 707 
giving many and varied answers, in the attempt to address all the rising issues, finding alternatives 708 
and engineering adequate systems to fulfill requirements and needs. One of the concerns is always 709 
the fate of the drug. In lung drug delivery, the objective is sometimes to retain the drug in the lung, 710 
as happens in local delivery approaches, thus minimising the systemic absorption. In other cases, a 711 
systemic effect is the desired outcome and the carriers are engineered to avoid retention. The options 712 
to address therapeutic demands are varied, as seen by the plethora of systems, alternatives and 713 
engineering possibilities described through the review. As expected, the global analysis reveals that 714 
most of the works focus on the use of the lung route to attain local rather than systemic effects. It was 715 
also verified that, from the three main topics explored in the review, the delivery of anticancer drugs 716 
is the one concentrating more proposals in the literature, which is justified by the severity of the 717 
numbers associated with this disease, the increasing number of patients and the lack of therapeutic 718 
options, apart from the marketing appeal of cancer therapies.  719 
Whichever the specific topic, it has become clear that the use of nanocarriers is an added value 720 
and may provide an evolution of therapeutic responses if used properly and the arising toxicological 721 
concerns are addressed. Furthermore, the engineering of different strategies mainly involved surface 722 
functionalisation of the carriers or at least took benefit of their components to provide specific effects. 723 
The latter is perhaps the strategy still requiring further investment to bring out all its potential, as 724 
smart polymers have emerged as a new range of powerful tools, but still need refinement. The use of 725 
the different physiological conditions, such as pH, temperature and redox compounds or even light 726 
at different wavelengths can be the answer to more targeted and efficent therapies. Objectivelly, the 727 
field needs clinically feasible formulations, which possibly could combine some of the different 728 
strategies that were described, certainly using some kind of surface engineering to reach specific 729 
biological targets, but also adjusting the desired properties with the use of materials that may respond 730 
specifically, either to stimuli or to the established characteristics of the target area. Recently, a very 731 
interesting and promising approach was reported in this context, comprising a nanoparticle-in-732 
microgel system that provides drug release triggered by the presence of proteases. As the presence 733 
of these enzymes is greatly increased in the lung as a consequence of the inflammatory processs 734 
related to asthma, COPD and cystic fibrosis, this may comprise a therapeutic strategy for the 735 
treatment of these conditions [134].Despite the tremendous advancement, the evolution of the field 736 
is in strong dependence of new knowledge being generated at more basic science, namely the 737 
molecular mechanisms of the diseases, which are great indicators of tools to be used in the 738 
development of new therapies. Additionally, it cannot be forgotten that many of the tools identified 739 
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as successful and providing improved therapeutic responses, that is, carriers and above all, the 740 
materials, are not approved so far by the regulatory entities for an application in lung delivery. This 741 
poses a great challenge itself. Addressing the toxicity of inhaled therapeutic nanocarriers is actually 742 
a matter of inescapable importance. For many years now it has become clear that the biocompatibility 743 
of nanomaterials is not that of the raw materials and its evaluation needs to go much beyond the 744 
assessment of the isolated components. The nanomaterial must be considered a new entity instead, 745 
within the context of a specific delivery route [135]. Therefore, generating data on the safety of the 746 
nanocarriers and the new materials identified as potential adjuvants, in the framework of the lung 747 
route, is currently understood as an urgent need to potentiate lung drug delivery applications. This 748 
should involve toxicity tests that evaluate all the possible toxicity pathways, both in vitro and in vivo, 749 
while ensuring that the 3Rs policy to reduce, refine and replace the use of animals in research is 750 
followed. The initial in vitro tests should address cytotoxicity and genotoxicity, and should also 751 
evaluate potential epigenetic toxicity [136]. The fate of the proper carriers after the delivery is often 752 
disregarded. A very recent study comparing the clearance kinetics of liposomes and solid lipid 753 
nanoparticles after IT delivery of suspensions to rats has shown similar clearance rates, despite 754 
different deposition patterns [137]. Studies around this topic are, thus, imperative to provide data on 755 
the safety of the materials and the kick-off to their clinical application.  756 
It is important to point out that, when in vivo assays were described, which occurred in a 757 
considerable number of the presented works, IT delivery of the nanocarriers was the predominant 758 
technique for the assessment, which implies a high risk when establishing possible correlations with 759 
human delivery. The fact that nanocarriers themselves do not exhibit suitable aerodynamics for 760 
inhalation is also a matter of relevance, as this always implies an extra step, tipically proposed to 761 
involve the spray-drying of nanocarriers to produce nano-in-microcarriers that can deposit in the 762 
lung. 763 
The area still needs to evolve in several topics before inhalable nanocarriers enter clinical trials. 764 
Not only the question of performing more realistic in vivo assays is determinant, but also the 765 
toxicological assessment plays a defining role. Helpful technologies have been arising, such as 3D 766 
printing, which was used on the printing of artificial airways that enable the study of particle 767 
flowability and dose assessment. Lim et al. describe this application in the neonate, showing a 768 
powerful tool to improve the ethics associated with formulation testing and to provide solutions to 769 
children born with respiratory complications [138]. 770 
All in all, this review highlighted an integrative process that considers progress made at the level 771 
of basic science, which clarifies pathophysiological aspects of each clinical condition, and the 772 
development of tools and strategies to reach the pharmacological targets. Many works were 773 
described with inhalable nanocariers that have been showing potential, even with the existing 774 
limitations. All the issues, however, point out to a common objective of providing the knowledge to 775 
enable the engineering of nanocarriers that will promote improved lung therapeutics. 776 
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